Skip to main content
. 2013 Feb 25;8(2):e56829. doi: 10.1371/journal.pone.0056829

Figure 2. hPEBP4 overexpression inhibited rituximab-mediated ADCC (antibody-dependent cell-mediated cytotoxicity) and CDC (complement-dependent cytotoxicity) in human lymphoma cells.

Figure 2

A. Raji cells were stably transfected with hPEBP4-B or mock vectors, and the expression of hPEBP4 was confirmed by Western blot analysis with anti-hPEBP4 antibody. B. Effects of hPEBP4 overexpression on rituximab-mediated ADCC and CDC. The CDC activity in Raji/hPEBP4-B and Raji/Mock using 10% NHS was measured using a standard LDH assay as described in the materials and methods. **, p<0.01 compared with mock transfected cells. C. Silencing of hPEBP4 sensitized Raji cells to rituximab-mediated ADCC and CDC. **, p<0.01 compared with shNC transfected cells. Results are mean±S.E. of three independent experiments. D. Longer survival of Raji/shPEBP4 bearing nude mice than of control groups when treated with rituximab (p<0.05). Representative of two independent experiments.